Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Long-term Safety Roll-over Study in TSC and Refractory Seizures
NCT02962414Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of everolimus in tuberous sclerosis complex (TSC), epilepsy, sponsored by Novartis. Started Aug 2017; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on NCT02962414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962414.